Abstract:Motivation: With the booming of interactome studies, a lot of interactions can be measured in a high throughput way and large scale datasets are available. It is becoming apparent that many different types of interactions can be potential drug targets. Compared with inhibition of a single protein, inhibition of protein-protein interaction (PPI) is promising to improve the specificity with fewer adverse side-effects. Also it greatly broadens the drug target search space, which makes the drug target discovery difficult. Computational methods are highly desired to efficiently provide candidates for further experiments and hold the promise to greatly accelerate the discovery of novel drug targets.Results: Here, we propose a machine learning method to predict PPI targets in a genomic-wide scale. Specifically, we develop a computational method, named as PrePPItar, to Predict PPIs as drug targets by uncovering the potential associations between drugs and PPIs. First, we survey the databases and manually construct a gold-standard positive dataset for drug and PPI interactions. This effort leads to a dataset with 227 associations among 63 PPIs and 113 FDA-approved drugs and allows us to build models to learn the association rules from the data. Second, we characterize drugs by profiling in chemical structure, drug ATC-code annotation, and side-effect space and represent PPI similarity by a symmetrical S-kernel based on protein amino acid sequence. Then the drugs and PPIs are correlated by Kronecker product kernel. Finally, a support vector machine (SVM), is trained to predict novel associations between drugs and PPIs. We validate our PrePPItar method on the well-established gold-standard dataset by cross-validation. We find that all chemical structure, drug ATC-code, and side-effect information are predictive for PPI target. Moreover, we can increase the PPI target prediction coverage by integrating multiple data sources. Follow-up database search and pathway analysis indicate that our new predictions are worthy of future experimental validation.Conclusion: In conclusion, PrePPItar can serve as a useful tool for PPI target discovery and provides a general heterogeneous data integrative framework.

Chemical-Protein Interactome and Its Application in Off-Target Identification

Methods to Profile the Macromolecular Targets of Small Compounds.

Identifying Unexpected Therapeutic Targets Via Chemical-Protein Interactome.

An Ensemble Learning-Based Method for Inferring Drug-Target Interactions Combining Protein Sequences and Drug Fingerprints

Computational Probing Protein-Protein Interactions Targeting Small Molecules.

Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity

Prediction of Chemical-Protein Interactions: Multitarget-Qsar Versus Computational Chemogenomic Methods

Therapeutic Target Identification and Drug Discovery Driven by Chemical Proteomics

A Computational Approach For Predicting Drug-Target Interactions From Protein Sequence And Drug Substructure Fingerprint Information

Targeting Peptide‐mediated Interactions in Omics

An Integrated Structure- and System-Based Framework to Identify New Targets of Metabolites and Known Drugs

Exploration of Target Spaces in the Human Genome for Protein and Peptide Drugs

DrugProtAI: A guide to the future research of investigational target proteins

Chemical Proteomics to Identify Molecular Targets of Small Compounds

Proteomics in Computer-Aided Drug Design

Computational Identification of Inhibitors of Protein-Protein Interactions.

Large-scale Prediction of Drug–target Interactions Using Protein Sequences and Drug Topological Structures

Artificial Intelligence/Machine Learning-Driven Small Molecule Repurposing via Off-Target Prediction and Transcriptomics

[Chemical Proteomics and Discovery of Drug Targets].

DRAR-CPI: a Server for Identifying Drug Repositioning Potential and Adverse Drug Reactions Via the Chemical-Protein Interactome.

Incorporating Chemical Sub-Structures and Protein Evolutionary Information for Inferring Drug-Target Interactions